Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

Efficacy of Neoadjuvant XELOX/AVASTIN Therapy for Nonresectable Colorectal Liver Metastases With Secondary Hepatic Resection/Radiofrequency

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00408772
• Other study ID #: 200412546
• Secondary ID: UCDCC#131CDR0000
• Status: Withdrawn
• Phase: Phase 2
• First received: December 6, 2006
• Last updated: June 7, 2017
• Start date: June 2007
• Est. completion date: April 2008

Study information

• Verified date: June 2017
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving chemotherapy and bevacizumab before surgery or radiofrequency ablation may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with bevacizumab followed by surgery and/or radiofrequency ablation works in treating patients with colorectal cancer that has spread to the liver and cannot be removed by surgery.

Description:

OBJECTIVES:

Primary

• Evaluate the conversion rate of nonresectable disease to resectable disease in patients with nonresectable liver metastases secondary to colorectal adenocarcinoma treated with neoadjuvant therapy comprising oxaliplatin, capecitabine, and bevacizumab followed by hepatic resection and/or radiofrequency ablation.

• Evaluate progression-free survival of patients treated with this regimen.

Secondary

• Determine disease-free and overall survival of patients treated with this regimen.

• Determine the toxicities of this regimen in these patients.

OUTLINE:

• Neoadjuvant therapy: Patients receive oxaliplatin IV over 2 hours and bevacizumab IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 4-6 courses in the absence of disease progression or unacceptable toxicity or until conversion to resectable disease.

• Surgery and/or radiofrequency ablation (RFA): Patients undergo hepatic resection (with or without RFA) when tumor is deemed resectable. Patients with stable (< 8 lesions) and unresectable disease undergo laparoscopic or percutaneous RFA. RFA repeats once 4-6 weeks later.

• Adjuvant therapy: Beginning 6-8 weeks after surgery and/or RFA, patients may receive adjuvant therapy comprising oxaliplatin, capecitabine, and bevacizumab, as in neoadjuvant therapy, for up to 4 courses.

After completion of study treatment, patients are followed every 4 months.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2008
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed colorectal adenocarcinoma metastatic to the liver

• Unresectable liver metastases

• Measurable disease

• No evidence of extrahepatic metastases

• No CNS metastases

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• Absolute neutrophil count > 1,500/mm^3

• Platelet count > 100,000/mm^3

• Creatinine = 1.5 times upper limit of normal (ULN) OR creatinine clearance = 45 mL/min

• Urinary protein < 2+ by dipstick OR < 2 g by 24-hour urine collection

• Bilirubin < 2 times ULN

• SGOT and SGPT < 2 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 18 months after completion of study therapy

• Able to take oral medications (e.g., no dysphagia or malabsorption symptoms)

• No other prior malignancy unless in complete remission and off therapy for = 5 years

• No known allergy to the study drugs

• No peripheral neuropathy > grade 1

• No uncontrolled infection

• No uncontrolled hypertension

• No active bleeding or hemoptysis

• No other serious concurrent illness within the past 12 months, including any of the following:

• Nonstable coronary artery disease

• Myocardial infarction

• Transient ischemic attack

• Cardiovascular accident

PRIOR CONCURRENT THERAPY:

• Recovered from prior therapy

• At least 28 days since prior major surgery

• Prior therapy for advanced disease allowed

• No prior oxaliplatin-based therapy

• Concurrent maintenance and palliative treatment during study chemotherapy allowed (e.g., nutritional or transfusional support or pain control)

• No concurrent corticosteroids except when used under the following circumstances:

• As oxaliplatin premedication

• Anti-5-HT_3 as antiemetic

• No concurrent cold cap or iced mouth rinses

• No other concurrent chemotherapy

• No placement of hepatic artery port for regional chemotherapy

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Metastatic Cancer
• Neoplasm Metastasis

Intervention

Biological:
• bevacizumab

Drug:
• capecitabine

• oxaliplatin

Procedure:
• conventional surgery

• neoadjuvant therapy

• radiofrequency ablation

Locations

Country	Name	City	State
United States	University of California Davis Cancer Center	Sacramento	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Davis	Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Conversion rate of nonresectable disease to resectable disease		48 months
Secondary	Disease-free and overall survival		48 months
Secondary	Objective response rate		48 months
Secondary	Duration of response		48 months